Log in
(Ad)
A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

NASDAQ:MTEM - Molecular Templates Stock Price, Forecast & News

$13.81
-0.64 (-4.43 %)
(As of 01/23/2020 06:12 AM ET)
Today's Range
$13.46
Now: $13.81
$14.67
50-Day Range
$10.69
MA: $13.02
$14.72
52-Week Range
$4.07
Now: $13.81
$15.05
Volume256,852 shs
Average Volume282,661 shs
Market Capitalization$510.56 million
P/E RatioN/A
Dividend YieldN/A
Beta3.18
Molecular Templates, Inc, a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:MTEM
CUSIP88580720
Phone512-869-1555

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$13.28 million
Book Value$2.75 per share

Profitability

Net Income$-30,290,000.00
Net Margins-289.90%

Miscellaneous

Employees68
Market Cap$510.56 million
Next Earnings Date3/26/2020 (Estimated)
OptionableNot Optionable

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.


(Ad)

A devastating technical glitch could crush the next generation of wireless technology before it even launches. With trillions of dollars and millions of jobs at stake, one company with the "5G fix" could put as much as $234,770 in your pocket this year. But Wall Street vultures are circling... you'll need to move quickly or risk missing this $5 bargain.

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Shares of Molecular Templates reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) posted its quarterly earnings results on Tuesday, November, 12th. The biotechnology company reported ($0.43) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.24) by $0.19. The biotechnology company had revenue of $3.62 million for the quarter, compared to analysts' expectations of $6 million. Molecular Templates had a negative net margin of 289.90% and a negative return on equity of 44.86%. View Molecular Templates' Earnings History.

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release their next quarterly earnings announcement on Thursday, March 26th 2020. View Earnings Estimates for Molecular Templates.

What price target have analysts set for MTEM?

2 brokers have issued 1-year target prices for Molecular Templates' shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Molecular Templates' stock price to reach $12.00 in the next year. This suggests that the stock has a possible downside of 13.1%. View Analyst Price Targets for Molecular Templates.

What is the consensus analysts' recommendation for Molecular Templates?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Molecular Templates.

Has Molecular Templates been receiving favorable news coverage?

Media headlines about MTEM stock have trended somewhat positive on Thursday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Molecular Templates earned a media sentiment score of 2.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View News Stories for Molecular Templates.

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest in December. As of December 31st, there was short interest totalling 1,260,000 shares, an increase of 10.5% from the December 15th total of 1,140,000 shares. Based on an average trading volume of 340,200 shares, the short-interest ratio is presently 3.7 days. Approximately 5.7% of the company's shares are sold short. View Molecular Templates' Current Options Chain.

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Alibaba Group (BABA), SLS International (SLS), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Walt Disney (DIS) and CEL-SCI (CVM).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the folowing people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $13.81.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $510.56 million and generates $13.28 million in revenue each year. The biotechnology company earns $-30,290,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.View Additional Information About Molecular Templates.

What is Molecular Templates' official website?

The official website for Molecular Templates is http://www.mtem.com/.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]


MarketBeat Community Rating for Molecular Templates (NASDAQ MTEM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  279 (Vote Underperform)
Total Votes:  575
MarketBeat's community ratings are surveys of what our community members think about Molecular Templates and other stocks. Vote "Outperform" if you believe MTEM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MTEM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel